Optimization of human mesenchymal stem cell manufacturing: The effects of animal/xeno-free media

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Oikonomopoulos, Angelos ^a   Van Deen, Welmoed K ^a,b   Manansala, Aida Rae ^a   Lacey, Precious N ^a   Tomakili, Tamera A ^a   Ziman, Alyssa ^a   Hommes, Daniel W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ALKALINE PHOSPHATASE; CELL EXTRACT; CULTURE MEDIUM; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3-DIOXYGENASE 1, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SERUM-FREE MEDIUM;

ADIPOGENESIS; ANIMAL; BONE DEVELOPMENT; BOVINE; CELL CULTURE TECHNIQUE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; FETUS BLOOD; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOBLOTTING; MESENCHYMAL STROMA CELL; METABOLISM; PHARMACOLOGY; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERUM; SERUM-FREE MEDIUM; THROMBOCYTE;

ADIPOGENESIS; ADIPONECTIN; ALKALINE PHOSPHATASE; ANIMALS; BLOOD PLATELETS; CATTLE; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL EXTRACTS; CELL PROLIFERATION; CULTURE MEDIA; CULTURE MEDIA, SERUM-FREE; FETAL BLOOD; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERFERON-GAMMA; MESENCHYMAL STROMAL CELLS; OSTEOGENESIS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM;

EID: 84946944203     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16570     Document Type: Article

References (49)

1. Ball, L. M. et al. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110, 2764-2767 (2007).
2. Bernardo, M. & Fibbe, W. Safety and efficacy of mesenchymal stromal cell therapy in autoimmune disorders. Annals of the New York Academy of Sciences 1266, 107-117 (2012).
3. Duijvestein, M., van den Brink, G. & Hommes, D. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. Journal of Crohn's & colitis 2, 99-205 (2008).
4. Duijvestein, M. et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 59, 1662-1671 (2010).
5. Garcia-Olmo, D., Garcia-Arranz, M. & Herreros, D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther 8, 1417-1423 (2008).
6. Kebriaei, P. et al. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 15, 804-811 (2009).
7. Le Blanc, K. et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363, 1439-1441 (2004).
8. Le Blanc, K. & Ringden, O. Mesenchymal stem cells: properties and role in clinical bone marrow transplantation. Curr Opin Immunol 18, 586-591 (2006).
9. Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105, 1815-1822 (2005).
10. Di Nicola, M. et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99, 3838-3843 (2002).
11. Friedenstein, A. J. et al. Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp Hematol 2, 83-92 (1974).
12. Krampera, M. et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101, 3722-3729 (2003).
13. Singer, N. G. & Caplan, A. I. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 6, 457-478 (2011).
14. Duijvestein, M. et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 29, 1549-1558 (2011).
15. Krampera, M. et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 24, 386-398 (2006).
16. Plumas, J. et al. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19, 1597-1604 (2005).
17. Ren, G. et al. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2, 141-150 (2008).
18. Halme, D. & Kessler, D. FDA regulation of stem-cell-based therapies. The New England journal of medicine 355, 1730-1735 (2006).
19. Heiskanen, A. et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 25, 197-399 (2007).
20. Ivan, A. & Indrei, L. L. Emergence of transmissible disorders, a continuous process-a new type of viral meningoencephalitis. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 104, 51-55 (2000).
21. Mackensen, A., Drager, R., Schlesier, M., Mertelsmann, R. & Lindemann, A. Presence of IgE antibodies to bovine serum albumin in a patient developing anaphylaxis after vaccination with human peptide-pulsed dendritic cells. Cancer immunology, immunotherapy: CII 49, 152-156 (2000).
22. Selvaggi, T. A., Walker, R. E. & Fleisher, T. A. Development of antibodies to fetal calf serum with arthus-like reactions in human immunodeficiency virus-infected patients given syngeneic lymphocyte infusions. Blood 89, 776-779 (1997).
23. Spees, J. et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Molecular therapy: the journal of the American Society of Gene Therapy 9, 747-803 (2004).
24. Sundin, M. et al. No alloantibodies against mesenchymal stromal cells, but presence of anti-fetal calf serum antibodies, after transplantation in allogeneic hematopoietic stem cell recipients. Haematologica 92, 1208-1223 (2007).
25. Tuschong, L., Soenen, S., Blaese, R., Candotti, F. & Muul, L. Immune response to fetal calf serum by two adenosine deaminasedeficient patients after T cell gene therapy. Human gene therapy 13, 1605-1615 (2002).
26. Shih, D. T. & Burnouf, T. Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion. New biotechnology 32, 199-211 (2014).
27. Abdelrazik, H., Spaggiari, G. M., Chiossone, L. & Moretta, L. Mesenchymal stem cells expanded in human platelet lysate display a decreased inhibitory capacity on T- and NK-cell proliferation and function. Eur J Immunol 41, 3281-3290 (2011).
28. Avanzini, M. A. et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica 94, 1649-1660 (2009).
29. Bernardo, M. et al. Ex vivo expansion of mesenchymal stromal cells. Best practice & research. Clinical haematology 24, 73-154 (2011).
30. Bieback, K. et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 27, 2331-2341 (2009).
31. Cholewa, D. et al. Expansion of adipose mesenchymal stromal cells is affected by human platelet lysate and plating density. Cell Transplantation 20, 1409-1422 (2011).
32. Crespo-Diaz, R. et al. Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant 20, 797-811 (2011).
33. Fekete, N. et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 14, 540-554 (2012).
34. Flemming, A. et al. Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol 31, 1143-1156 (2011).
35. Gruber, R. et al. Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets 15, 29-35 (2004).
36. Hemeda, H., Giebel, B. & Wagner, W. Evaluation of human platelet lysate versus fetal bovine serum for culture of mesenchymal stromal cells. Cytotherapy 16, 170-180 (2014).
37. Kilian, O. et al. Effects of platelet growth factors on human mesenchymal stem cells and human endothelial cells in vitro. Eur J Med Res 9, 337-344 (2004).
38. Lange, C. et al. Accelerated and safe expansion of human mesenchymal stromal cells in animal serum-free medium for transplantation and regenerative medicine. J Cell Physiol 213, 18-26 (2007).
39. Lohmann, M. et al. Donor Age of Human Platelet Lysate Affects Proliferation and Differentiation of Mesenchymal Stem Cells. PLoS ONE 7, e37839 (2012).
40. Schallmoser, K. & Strunk, D. Preparation of Pooled Human Platelet Lysate (pHPL) as an Efficient Supplement for Animal Serum-Free Human Stem Cell Cultures. J Vis Exp 32, e1523 (2009).
41. Walenda, G. et al. Human platelet lysate gel provides a novel three dimensional-matrix for enhanced culture expansion of mesenchymal stromal cells. Tissue engineering. Part C, Methods 18, 924-934 (2012).
42. Agata, H. et al. Feasibility and efficacy of bone tissue engineering using human bone marrow stromal cells cultivated in serum-free conditions. Biochem Biophys Res Commun 382, 353-358 (2009).
43. Chase, L. G., Lakshmipathy, U., Solchaga, L. A., Rao, M. S. & Vemuri, M. C. A novel serum-free medium for the expansion of human mesenchymal stem cells. Stem cell research & therapy 1, 8 (2010).
44. Chase, L. G. et al. Development and Characterization of a Clinically Compliant Xeno-Free Culture Medium in Good Manufacturing Practice for Human Multipotent Mesenchymal Stem Cells. Stem Cells Translational Medicine 1, 750-758 (2012).
45. Lindroos, B. et al. Serum-free, xeno-free culture media maintain the proliferation rate and multipotentiality of adipose stem cells in vitro. Cytotherapy 11, 958-972 (2009).
46. Patrikoski, M. et al. Development of fully defined xeno-free culture system for the preparation and propagation of cell therapy-compliant human adipose stem cells. Stem cell research & therapy 4, 27 (2013).
47. PRNewswire, FDA Grants 510(k) Clearance to Life Technologies Stem Cell Growth Medium. (2011) Available at: http://www.prnewswire.com/news-releases/fda-grants-510k-clearance-to-life-technologies-stem-cell-growth-medium-117920569.html. (Accessed: August 25, 2015).
48. Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315-317 (2006).
49. Menard, C. et al. Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 22, 1789-1801 (2013).